Drug Shortage Active
TIGLUTIK KIT is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
TIGLUTIK KIT (riluzole) by Italfarmaco Research is 12. First approved in 2018.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
TIGLUTIK KIT is an oral suspension formulation of riluzole, a benzothiazole small molecule indicated for amyotrophic lateral sclerosis (ALS). The mechanism of action in ALS remains unknown, though riluzole is believed to exert neuroprotective effects through multiple pathways. This product represents a reformulation of the original riluzole tablet to improve patient convenience and adherence.
Product is approaching loss of exclusivity (2029), signaling a transition from growth to defensive strategy with likely smaller, specialized team focused on patient retention.
12.1 Mechanism of Action The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown. 12.2 Pharmacodynamics The clinical pharmacodynamics of riluzole has not been determined in humans. 12.3 Pharmacokinetics Table 2 displays the pharmacokinetic parameters of…
Benzothiazole
Worked on TIGLUTIK KIT at Italfarmaco Research? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
TIGLUTIK KIT offers limited career growth opportunity given LOE approach in 2.7 years and zero currently linked positions. Roles on this product focus on maximizing remaining exclusivity period and defending against generic erosion through patient relationships and specialty distribution networks.